Rugo H - Search Results

1

Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer.

Rugo H, Shtivelman E, Perez A, Vogel C, Franco S, Tan Chiu E, Melisko M, Tagliaferri M, Cohen I, Shoemaker M, Tran Z, Tripathy D. Rugo H, et al. Breast Cancer Res Treat. 2007 Sep;105(1):17-28. doi: 10.1007/s10549-006-9430-6. Epub 2006 Nov 17. Breast Cancer Res Treat. 2007. PMID: 17111207 Clinical Trial.

2

MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer.

Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N. Esserman L, et al. Among authors: rugo h. Ann Surg Oncol. 2001 Jul;8(6):549-59. doi: 10.1007/s10434-001-0549-8. Ann Surg Oncol. 2001. PMID: 11456056

3

Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable.

Gralow J, Rugo H, Gradishar W, O'Shaughnessy JA, Jahanzeb M, Perez E, Tripathy D. Gralow J, et al. Among authors: rugo h. Clin Breast Cancer. 2008 Feb;8(1):33-7. doi: 10.3816/CBC.2008.n.046. Clin Breast Cancer. 2008. PMID: 18501057 Review.

4

Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials.

Rugo H, Brammer M, Zhang F, Lalla D. Rugo H, et al. Clin Breast Cancer. 2010 Aug 1;10(4):288-93. doi: 10.3816/CBC.2010.n.037. Clin Breast Cancer. 2010. PMID: 20705561

5

Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer.

Albain KS, Carey L, Gradishar WJ, Gralow JR, Lipton A, Rugo H, Tripathy D, Peck S, Abair T, Pegram M. Albain KS, et al. Among authors: rugo h. Clin Breast Cancer. 2010 Dec 1;10(6):421-39. doi: 10.3816/CBC.2010.n.056. Clin Breast Cancer. 2010. PMID: 21147685 Review.

6

A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.

McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN. McArthur HL, et al. Among authors: rugo h. Clin Cancer Res. 2011 May 15;17(10):3398-407. doi: 10.1158/1078-0432.CCR-10-1969. Epub 2011 Feb 24. Clin Cancer Res. 2011. PMID: 21350003 Free PMC article. Clinical Trial.

7

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.

Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. Munster PN, et al. Among authors: rugo h. Br J Cancer. 2011 Jun 7;104(12):1828-35. doi: 10.1038/bjc.2011.156. Epub 2011 May 10. Br J Cancer. 2011. PMID: 21559012 Free PMC article. Clinical Trial.

8

Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment.

Lorizio W, Rugo H, Beattie MS, Tchu S, Melese T, Melisko M, Wu AH, Lawrence HJ, Nikoloff M, Ziv E. Lorizio W, et al. Among authors: rugo h. Genome Med. 2011 Oct 4;3(10):64. doi: 10.1186/gm280. Genome Med. 2011. PMID: 21970596 Free PMC article.

9

Clinical and biomarker predictors of side effects from tamoxifen.

Lorizio W, Wu AH, Beattie MS, Rugo H, Tchu S, Kerlikowske K, Ziv E. Lorizio W, et al. Among authors: rugo h. Breast Cancer Res Treat. 2012 Apr;132(3):1107-18. doi: 10.1007/s10549-011-1893-4. Epub 2011 Dec 30. Breast Cancer Res Treat. 2012. PMID: 22207277 Free PMC article.

10

Patient perceptions of reproductive health counseling at the time of cancer diagnosis: a qualitative study of female California cancer survivors.

Niemasik EE, Letourneau J, Dohan D, Katz A, Melisko M, Rugo H, Rosen M. Niemasik EE, et al. Among authors: rugo h. J Cancer Surviv. 2012 Sep;6(3):324-32. doi: 10.1007/s11764-012-0227-9. Epub 2012 Jul 3. J Cancer Surviv. 2012. PMID: 22752834

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

615 results

Search Page

Filters